FDA Grants Accelerated Approval to Sevabertinib for Non-Squamous NSCLC By Ogkologos - November 27, 2025 84 0 Facebook Twitter Google+ Pinterest WhatsApp It also approved a companion diagnostic device to aid in detecting HER2 tyrosine kinase domain activating mutations Source RELATED ARTICLESMORE FROM AUTHOR Lung Cancer Death Rates Among Women in Europe Are Finally Levelling Off A Combination of Savolitinib and Osimertinib Prolongs PFS in Patients with EGFR-mutated NSCLC and Acquired MET Amplification After Progression On a First-Line EGFR TKI EMA Recommends Granting a Conditional Marketing Authorisation for Nogapendekin alfa Inbakicept MOST POPULAR Radio Hosts Test Sanity For Charity By Listening to ‘Baby Shark’... November 20, 2019 Worries About Medical Bills May Worsen Health Outcomes After Cancer Diagnosis March 13, 2021 Man Met A Stranger At A Bar Who Was In Need... December 26, 2021 FDA Grants Accelerated Approval to Zongertinib for Non-squamous NSCLC with HER2... August 29, 2025 Load more HOT NEWS Genetic discovery could guide treatment for aggressive childhood cancer Consuming Poultry Could Lower Your Breast Cancer Risk As Much As... Fears breast cancer progress could stall due to COVID-19 backlog Hospital’s Team Of “Dog-Tors” Helps Sick Kids Feel Less Scared Of...
